Larotrectinib
Brand Name: Vitrakvi
Manufacturer: Bayer
Indication
Indication:
For the treatment of adult and pediatric patients with colorectal cancer (CRC) that displays a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Specific CRC Subtype: NTRK gene fusion
Stage: IV
Therapy Line: Third-line or later
Health Canada Approval: Approved
pCPA Negotiation Status: Completed
Reimbursed in:
New Search
